Urinary Obstruction News and Research

RSS
Optilume BPH Catheter System offers a safe and effective treatment for benign prostatic hyperplasia

Optilume BPH Catheter System offers a safe and effective treatment for benign prostatic hyperplasia

Study finds new drug combination to be more effective against complicated urinary tract infections

Study finds new drug combination to be more effective against complicated urinary tract infections

Pregnancy increases the risk of first-time symptomatic kidney stone

Pregnancy increases the risk of first-time symptomatic kidney stone

Researchers describe histological features of urinary obstruction in humans for the first time

Researchers describe histological features of urinary obstruction in humans for the first time

Alnylam announces positive results from Phase 1/2 study of lumasiran for treating primary hyperoxaluria-1

Alnylam announces positive results from Phase 1/2 study of lumasiran for treating primary hyperoxaluria-1

Alnylam announces new positive results from Phase 1/2 study of lumasiran in patients with PH1

Alnylam announces new positive results from Phase 1/2 study of lumasiran in patients with PH1

FDA approves Novartis’ Exelon Patch to treat mild to moderate AD

FDA approves Novartis’ Exelon Patch to treat mild to moderate AD

Surprising life-quality benefit from early prostate cancer treatment

Surprising life-quality benefit from early prostate cancer treatment

Prostate size and other neglected factors influence prostate cancer treatment satisfaction

Prostate size and other neglected factors influence prostate cancer treatment satisfaction

New research could affect future treatment options for prostate cancer

New research could affect future treatment options for prostate cancer

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.